Deltex Medical Group Plc engages in manufacturing and sale of advanced haemodynamic monitoring technologies. The company is headquartered in Chichester, West Sussex and currently employs 37 full-time employees. The firm develops, manufactures and distributes a hemodynamic monitoring technology. The firm's TrueVue platform offers three monitoring technologies, such as Oesophageal Doppler Monitoring (ODM+), Pulse Pressure Waveform Analysis (PPWA) and High Definition Impedance CardioGraphy (HD-ICG). Its ODM+ is a fluid management and cardiac output monitoring technology to directly measure both flow and pressure in adults and pediatrics. HD-ICG provides continuous and sensitive measurements of cardiac output and other hemodynamic parameters. The system is stabilized using HD-Z signal filter technology. HD-ICG disposable electrodes are placed on the neck and chest. PPWA uses the researched pulse pressure wave algorithm, which is available to derive hemodynamic parameters, calibrated from the Doppler. Its applications include surgery, acute kidney injury, enhanced recovery, paediatric, and COVID-19 critical care.
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for DTXMF. Our analysts highlight strong fundamentals and favorable market sentiment, positioning DTXMF for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: DTXMF is a Strong Buy candidate.
DTXMF stock price ended at $0.1 on 水曜日, after dropping NaN%
On the latest trading day Feb 05, 2025, the stock price of DTXMF fell by NaN%, dropping from $0.10 to $0.10. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $0.10 and a high of $0.10. On the latest trading day, the trading volume for DTXMF decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 302 shares were traded, with a market value of approximately $189.6M.